Navigation Links
AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
Date:10/25/2007

with clonogenic growth of human xenograft derived cell lines.

Conclusions

- All three AEZS-112 follow-up candidates were equal to or more efficient

in exerting cytotoxic activity in tumor cell lines and inhibiting

tubulin polymerization than AEZS-112, whereas induction of cell cycle

arrest and apoptosis was slightly improved;

- An interesting difference to the AEZS-112 profile is the inhibition of

topoisomerase I by compounds 2 and 3. Moreover, compound 2 displayed

significant higher potency for topoisomerase II inhibition than

AEZS-112;

- In vitro plasma and liver microsomal stability of the follow-up

candidates are comparable to AEZS-112, thus demonstrating suitability

for in vivo efficacy studies;

- Interference with clonogenic growth of xenograft-derived cells revealed

variability in the response of the different tumor classes to AEZS-112

and compound 1 treatment as a basis for selection of the most

appropriate in vivo efficacy models.

Based on their interesting in vitro profiles, all three follow-up candidates will be subjected to human tumor xenograft in vivo models aimed at selecting an AEZS-112 follow-up candidate for preclinical development.

The poster presentation is available in the Investor section of the Company's website under "Events and Webcasts" at http://www.aeternazentaris.com.

About AEZS-112

AEZS-112 is a novel oral multi-targeted cytotoxic compound with inhibitory effects on tubulin polymerization, topoisomerase II and angiogenesis. In January 2007, the Company initiated a Phase 1 clinical trial for solid tumors and lymphoma; primary endpoints will focus on determining the safety and tolerability of the compound.

AEZS-112 has shown potent in vitro anti-proliferative activity at nanomolar concentrations against human tumor cell lines of diff
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. A Further Step in Understanding Apoptosis Direct Detection of PARP Cleavage
2. OpGen recruits CEO to further gene-mapping business
3. Better collaboration urged to further Wisconsin biotech
4. Johnson Controls jumping further into hybrid-vehicle battery world
5. The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
6. RNArticles: RNA Amplification Used to Develop a New In Vitro HCMV Assay
7. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
8. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
9. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
10. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
11. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Convey Computer , ... team from Iowa State University won first place in ... a Convey HC-2ex, the team’s solution achieved the highest ... than the second place finisher. , Experts from all ... the month long challenge, using a variety of design ...
(Date:10/20/2014)... , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... which brings Q3 orders to $5.8 million and provides a good ... in North America and one in the ... bid new projects at record levels," said Peter Bruijns , ... at the end of Q3 than they have been for any ...
(Date:10/20/2014)... 20, 2014  GenVec, Inc. (NASDAQ: GNVC ) ... Ph.D., from its board of directors effective on October 24, ... and served as its chairman from June 2006 to November ... and Corporate Governance and Audit Committees of the board.  ... decade of dedicated service to GenVec, and its stockholders," said ...
(Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... Health, Labor and Welfare (MHLW), for the revolutionary medical ... ... blood, IRVINE, Calif., Nov. 27 Masimo, the inventor,of ... announced approval of the Masimo Rad-57 Pulse CO-Oximeter,bringing the world,s ...
... Research &,Instrumentation, Inc. (CRi) announces the launch of ... Maestro 2 received widespread acclaim,at the both the ... conference for in vivo imaging, and at the ... 2, the fully,automated version of the award-winning Maestro ...
... 26 Pharmacopeia,(Nasdaq: PCOP ), an innovator in ... announced that Dr. Leslie J. Browne,President and Chief Executive ... Focus on Healthcare Conference hosted by,BMO Capital Markets. The ... Broadway Hotel in New York City., Dr. Browne,s ...
Cached Biology Technology:Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 2Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 3Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 4CRi Announces Maestro 2, the Next Generation in Vivo Optical Imaging Systems 2Pharmacopeia To Present at BMO Capital Markets' Seventh Annual Focus on Healthcare Conference 2Pharmacopeia To Present at BMO Capital Markets' Seventh Annual Focus on Healthcare Conference 3
(Date:10/16/2014)... monocultures can be cultivated efficiently, they are anything ... caused by monoculture cultivation is becoming increasingly evident. ... crop form and are regarded as the sole ... – quite wrongfully, finds Bernhard Schmid, an ecology ... a novel form of agriculture and forestry. After ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... edge technologies including Wocket™, the Smart Wallet, at the ... FiRe is a leading global conference on the intersection ... by Mark Anderson , founder and publisher of ...
(Date:10/15/2014)... biophysics textbook and it describes how life functions and ... into biological systems and provides an understanding of the ... how our genes make proteins that control the dynamics ... an organism. It quantifies the principles of life and ... on both large and small scales. The book is ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3New book about life as seen from physics 2
... PA, October 28, 2008 A growing body of ... from grapes, including red wine, helps reduce the risk ... the November issue of Nutrition Research . ... such as red wine may be beneficial in preventing ...
... However, how the step from gene to anti-bacterial effect occurs ... B. Pseudomallei, a bacterium suitable for bioweapons, had managed ... body for many years without being detected by the immune ... the body, resulting in the patient dying from blood poisoning. ...
... event organised by the trinational Transalpine Biocluster ... will bring together researchers and professionals from academia ... the most recent findings in the fields of ... new and exciting developments in the technology and ...
Cached Biology News:Mounting evidence shows health benefits of grape polyphenols 2Bridging public and private research on bioinformatics and proteomics 2
... is a G1 cyclin required for G1-phase ... a proto-oncogene. cyclin D2 can phosphorylate ... Species Reactivity: Human, Mouse, and Rat. ... is particularly well suited for neutralization of ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
... for 25 chips provides the chips and ... (at picogram levels) with the Experion automated ... HighSens microfluidic chips, 2 x 1,250 microliters ... HighSens stain, 20 microliters RNA ladder, 2 ...
Biology Products: